EUVIMEDEUVIMED entdecken
Crossref

Repurposing the non-steroidal anti-inflammatory drug diflunisal as an adjunct therapy with amphotericin B against mucoralean fungi

Anjna Kumari, Jasdeep Kaur, Pallavi Sharma, Mahaldeep Kaur, Rachna Singh

Journal of Medical Microbiology · 2024

DOI: 10.1099/jmm.0.001929 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Microbiology, 2024. Verfasst von Anjna Kumari und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbial Biotechnology, Panjab University, Chandigarh 160014, India. Hauptthemen laut MEDLINE: Antifungal Agents, Amphotericin B, Mucorales, Microbial Sensitivity Tests. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Indian Council of Medical Research, SERB Early Career Research Award.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Mucormycosis is an aggressive, angioinvasive infection associated with high morbidity and mortality. The disease remains difficult to treat, with limited available antifungal drugs. Consequently, there is an urgent need to develop alternate therapeutics against mucormycosis. In an earlier study, we demonstrated that the non-steroidal anti-inflammatory drug diflunisal impacted the actin cytoskeleton and quorum sensing and inhibited the formation of filopodia-/cytoneme-like extensions in Rhizopus arrhizus . Hypothesis. The non-steroidal anti-inflammatory drug diflunisal could exhibit potential antifungal activity.

Aim

This study aimed to investigate the plausible antifungal activity of diflunisal against a range of medically important Mucorales and its combination effect with antifungal drugs. Methodology. The antifungal activity of diflunisal against Rhizopus arrhizus, Lichtheimia corymbifera, Rhizomucor pusillus , Cunninghamella bertholletiae , Mucor indicus, Mucor irregularis and Apophysomyces elegans was evaluated by broth microdilution assay. Allied salicylates were also screened. A combination assay with amphotericin B deoxycholate and posaconazole was performed by fractional inhibitory concentration test.

Results

Exposure to diflunisal inhibited Rhizopus arrhizus spore germination in a dose-dependent manner. MICs of diflunisal against different Mucorales ranged from 64 to 2048 µg ml −1 . Remarkably low levels of diflunisal (0.03–2 µg ml −1 ), depending on the strain/species tested, improved the antifungal activity of amphotericin B against mucoralean fungi by twofold (ΣFIC ≈ 0.5–0.508; P< 0.01). Field-emission scanning electron micrographs further confirmed these observations. MICs of posaconazole were unchanged by this compound.

Conclusion

Considering that amphotericin B remains the first-line drug against mucormycosis and exhibits dose-dependent side effects in clinical practice, especially nephrotoxicity, the observed additive interaction at remarkably low, clinically achievable levels of diflunisal demonstrates its potential utility as an adjunct therapy against mucoralean fungi.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsAmphotericin BMucoralesMicrobial Sensitivity TestsDrug RepositioningDiflunisalMucormycosisAnti-Inflammatory Agents, Non-SteroidalHumansDrug Synergism

Stichwörter der Autor:innen

MucorRhizopusamphotericin Bdiflunisalmucormycosis

Substanzen

Antifungal AgentsAmphotericin BDiflunisalAnti-Inflammatory Agents, Non-Steroidal

Autor:innen und Institutionen

  • Department of Microbial Biotechnology, Panjab University, Chandigarh 160014, India.
  • Present address: Laboratory of Clinical Immunology and Microbiology, Epithelial Therapeutics Unit, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD 20892, USA.

Förderung

  • Indian Council of Medical Research
  • SERB Early Career Research Award

Zitieren

APA

Kumari, A., Kaur, J., Sharma, P., Kaur, M., & Singh, R. (2024). Repurposing the non-steroidal anti-inflammatory drug diflunisal as an adjunct therapy with amphotericin B against mucoralean fungi. Journal of Medical Microbiology. https://doi.org/10.1099/jmm.0.001929

Vancouver

Kumari A, Kaur J, Sharma P, Kaur M, Singh R. Repurposing the non-steroidal anti-inflammatory drug diflunisal as an adjunct therapy with amphotericin B against mucoralean fungi. Journal of Medical Microbiology. 2024. doi:10.1099/jmm.0.001929

BibTeX
@article{Kumari2024,
  author = {Kumari, Anjna and Kaur, Jasdeep and Sharma, Pallavi and Kaur, Mahaldeep and Singh, Rachna},
  title = {Repurposing the non-steroidal anti-inflammatory drug diflunisal as an adjunct therapy with amphotericin B against mucoralean fungi},
  journal = {Journal of Medical Microbiology},
  year = {2024},
  doi = {10.1099/jmm.0.001929}
}
Kostenlos starten →